SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-294159
Filing Date
2021-10-07
Accepted
2021-10-07 16:06:03
Documents
14
Period of Report
2021-10-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d181647d8k.htm   iXBRL 8-K 24784
2 EX-99.1 d181647dex991.htm EX-99.1 33073
6 GRAPHIC g181647g1007200304830.jpg GRAPHIC 2537
  Complete submission text file 0001193125-21-294159.txt   196407

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20211007.xsd EX-101.SCH 2898
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20211007_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20211007_pre.xml EX-101.PRE 11864
7 EXTRACTED XBRL INSTANCE DOCUMENT d181647d8k_htm.xml XML 3486
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 211312454
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences